Prospective, multi-center, single arm, open label clinical trial.
IoNIR - IonMAN
Enrollment
Completed
4 Sites
60 Patients
Primary Endpoints
2. TLF at 12 months.
Prospective, multi-center, single arm, open label clinical trial.
Enrollment
Completed
4 Sites
60 Patients
Primary Endpoints
Prospective, multi-center, open-label, single arm, post marketing clinical trial
Study
Completed
18 Sites
316 Patients
Primary Endpoint
Prospective, multi-center, open-label, single arm clinical trial
Study
Completed
10 Sites
104 Patients
12 Months
Primary Endpoint
Prospective, multi-center, single-blind, two-arm, randomized clinical trial
Study
Completed
76 Sites
1,919 Patients
5.4% TLF
0.4% ST 24 Months
Target Lesion Failure 12 Months
Stent Thrombosis 24 Months
Prospective, multi-center, single-blind, two-arm, randomized clinical trial
Study
Completed
31 Sites
302 Patients
Primary Endpoint
In Stent Late-Loss 6 Months (mm)
Target Lesion Failure/Mace 12 Months
Prospective, multi-center, single arm, open label clinical trial.
Study
Completed
9 Sites
81 Patients
Primary endpoints
Prospective, multi-center, single-arm, open-label clinical trial
Study
Completed
6 Sites
50 Patients
Primary endpoint